R E T U R N M E N U |
Dietary Lycopene
and Plasma/Serum Lycopene |
C R I T I C A L F I N D I N G S |
|
CARDIOVASCULAR DISEASE (CVD)
Lycopene Supplementation and Disease Risk
CVD - main findings
- The data for lycopene or tomato extract supplementation are predominantly from smaller size studies. Both favorable and neutral outcomes are reported; however, 2 larger size RCT studies (n=400 and n=175) indicate a neutral relationship between lycopene supplementation and heart disease risk reduction.
- Inconclusive evidence for benefits in blood pressure regulation; although combination therapy (lycopene plus low dose standard of care medication) may provide benefit.
- Evidence for improving oxidative stress status.
- Limited evidence for modulation of inflammatory status or endothelial function
- Modest support for effects on platelet function as demonstrated by fresh fruit extracts (FTE).
Summary of studies and outcomes
- Number of studies = 24
- Risk estimates (RE) = 29
- (-) = 16
- N = 13
- (+) = 0
- Risk estimates by Tomato or Lycopene category
- √GT G. Tom =
- √PT P. Tom = 1 (-)
- √FTE FTE = 2 (-)
- √Lyco Lyco = 13 (-), 13 (N)
